Vol. 23/No. 7

As technology and cancer care continue to become intertwined at every level, there is an imperative need to effectively process and use vast amounts of data to provide the highest level of care for patients.

Marcia S. Brose, MD, PhD, FASCO, and a panel of thyroid cancer experts share their insights into the evolving treatment landscape, including the use of VEGF receptor inhibitors and some of the precision medicine treatments now identified for molecularly selected subsets of patients with differentiated thyroid cancer, such as BRAF, RET, and TRK inhibitors.

Elias J. Jabbour, MD, and Matthew S. Davids, MD, MMSc, review data on asciminib and ponatinib in the post–second generation TKI setting for chronic myeloid leukemia that were presented at the 2021 ASH Meeting and Exposition.

Specialization in oncology research affords investigators the opportunity to dive into tumor biology and uncover unique approaches to care.

Patients who develop post–essential thrombocythemia myelofibrosis or post–polycythemia vera myelofibrosis, which are associated with significant symptom burden and bone marrow failure, have limited therapies available for effective treatment.

Maurie Markman, MD, discusses the obstacles between implementing clinical trial data into practice.